04-15-24
CVRx announces availability of additional data supporting long-term benefits of Barostim
01-29-24
Allina Health’s Abbott Northwestern Hospital is First in Minnesota to Implant Barostim Therapy to Improve Symptoms of Heart Failure
11-03-22
CVRx Launches New Barostim NEO2 Implantable Pulse Generator
07-11-22
CVRx Launches a new Barostim™ Programmer
05-09-22
CVRx® Receives MR - Conditional Labeling Approval for its Barostim™ Heart Failure System
06-10-21
CVRx® Announces First Clinical Procedure with a New Ultrasound-Guided Implant Approach, the Latest Advancement in Barostim™ for the Treatment of Heart Failure Symptoms
06-09-21
Response by Sex in Patient-Centered Outcomes With Baroreflex Activation Therapy in Systolic Heart Failure
04-07-21
Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States
01-05-21
CVRx® Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing
12-03-20
CVRx® BAROSTIM Therapy Receives CMS Approval for Transitional Pass-Through Payment Status
11-18-20
CVRx® Announces New CFO and Acceleration of Barostim Therapy Commercialization Efforts
10-01-20
CVRx’s BAROSTIM NEO™ Receives CMS NTAP
08-29-20
See the Poster Here: Quality of Life Response to BAROSTIM THERAPY
See the Poster Here: Symptomatic Endpoint Responder Rates to BAROSTIM THERAPY
07-31-20
Does Neuromodulation Using Baroreflex Activation Therapy (BAT) have Potential Application in HFpEF?
07-21-20
News release: CVRx® Completes Enrollment of the BeAT-HF Phase III Randomized Clinical Trial, Continues to collect Morbidity and Mortality Outcomes
07-07-20
News release: CVRx® Raises $50 Million in New Equity Financing
07-01-20
Cardiology News: Women Thrive on Baroreflex Activation for Heart Failure
06-30-20
News release: CVRx® Announces Publication of BeAT-HF Clinical Study Results in the Journal of The American College of Cardiology
Read the Publication Here: BeAT-HF Clinical Study Results in the Journal of The American College of Cardiology
Editorial Accompanying the JACC Publication of BeAT-HF Clinical Study Results
06-23-20
News release: BAROSTIM™ NEO Associated with Very High Responder Rates in Women
06-19-20
See the Poster Here: BAROSTIM THERAPY in Patients with Heart Failure with a Reduced Ejection Fraction, Impact in Women
BAROSTIM NEO™ Reduces Heart Failure Symptoms for Patients with Atrial Fibrillation and/or LVEF < 25%
BAROSTIM NEO™ provides significant improvements in quality of life and exercise capacity, with high responder rates in women
05-07-20
BAROSTIM NEO™ Heart Failure Treatment Results in High Responder and Super-Responder Rates
BAROSTIM NEO™ Shows a Reduction in Serious Cardiovascular Events
BAROSTIM NEO™ Reduces Heart Failure Symptoms for Patients with or without Atrial Fibrillation
BAROSTIM NEO™ Reduces the Institutional Cost Burden of Heart Failure
08-16-19
News release: CVRx® Receives FDA Approval for World’s First Heart Failure Neuromodulation Device
05-27-19
BeAT-HF Pivotal Study Results Presented at ESC-HF
05-09-19
BeAT-HF Pivotal Study Results Presented at HRS
06-11-16
HOPE4HF 12 Month Data
11-19-15
News release: CVRx® Announces Expedited Access Pathway Designation by FDA
05-27-15
News release: CVRx® Barostim Therapy® for Heart Failure Clinical Trial Results Presented in the Late-Breaking Clinical Session of the ESC-Heart Failure 2015 Annual Conference
05-26-15
News release: CVRx® Barostim Therapy® for Heart Failure Clinical Trial Results Presented in the Late-Breaking Clinical Trial Session of the Heart Rhythm Society 2015 Annual Conference
03-18-15
BAT in HF 12 Month Data
03-17-15
News release: CVRx® Barostim Therapy™ for Heart Failure Clinical Trial Results Presented in a Featured Clinical Research Session of the American College of Cardiology Annual Conference
12-16-14
News release: CVRx® Granted Humanitarian Device Exemption Approval from FDA for Barostim neo legacy™ Hypertension Therapy Device
12-11-14
News release: CVRx® Granted CE Marking of the Barostim neo System™ for Conditional MRI Compatibility
09-29-14
News release: CVRx® Receives CE Mark Approval of the Barostim neo System™ for the Treatment of Heart Failure
07-28-14
BAT in HF Phase I Clinical Study Results
01-07-14
News release: Barostim Therapy™ Projected to be Cost-Effective in Treating Resistant Hypertension
08-25-11
News release: CVRx® Receives CE Mark Approval and Introduces New Implantable Device for Hypertension, the Barostim neo™
10-31-07
News release: CVRx®, Inc. Receives CE Mark Approval for Rheos® Baroreflex Hypertension Therapy™ System
09-18-06
News release: CVRx, Inc. Appoints Nadim Yared President and CEO
